Holds inaugural meeting with prominent
physicians, scientists and advocacy groups
TORONTO, June 27, 2019 /CNW/ - Pure Global Cannabis
Inc. (TSX.V: PURE; OTC: PRCNF; FRA: 1QS) ("Pure Global"), an
integrated growth-oriented sciences and consumer products cannabis
company, operating through its wholly-owned subsidiary PureSinse
Inc. ("PureSinse" or "Company"), recently completed a
very successful, inaugural PureSinse Medical Advisory Committee
(PMAC) meeting with a number of prominent physicians and scientists
from various disciplines. The meeting provided deep insights into
the physicians' daily practice, how cannabis impacts their
prescribing, and how PureSinse can differentiate in medical and
pharma drug development categories.
This first PMAC meeting brought together members representing a
variety of different disciplines and facets of the medical
committee. As a group, committee members provided direct feedback
to inform and guide PureSinse's decision-making in allocating
resources to high-need and underserved markets. Members are
practicing physicians in primary care, oncology, infectious
diseases, psychiatry, and other specialties. The committee also has
non-voting members who act as patient representatives, and
community and pharmacy industry representatives.
Pure Global CEO & President, Malay Panchal said, "We are
very pleased to be able to assemble a very high calibre Medical
Advisory Committee, created to receive direct feedback and advice
on developing our strategies for the medical cannabis sector. The
feedback will be invaluable in creating our educational, outreach
programs that provide guidance on medical cannabis use for
physicians and patients. The committee deliberations will also help
us focus our clinical medical priorities and offer guidance on
engagement activities to support the medical community."
Bringing together their wealth of medical and industry
experience, PMAC works to provide strategic direction and
recommendations to the PureSinse Executive Leadership Team (ELT).
The ongoing support of PMAC will cement PureSinse as a trusted
provider of education, products, and services for medical cannabis
users and prescribers. Direct input and guidance from PMAC will
also work to establish PureSinse as a unique brand, grounded in
trust and commitment to patients and the medical community.
This meeting of PMAC demonstrated that there is a large demand,
and need, for education on the medical benefits of cannabis.
PureSinse will use this guidance to tailor educational resources,
which provide medical evidence of these benefits, for patients and
clinicians. PureSinse will also create an ambassador and mentorship
program with a goal to help physicians learn about medical cannabis
on a peer-to-peer basis.
Mr. Panchal added: "As more patients become interested in adding
medical cannabis to their treatment options, these types of
educational resources will continue to be in high demand. Building
our brand around trust and education is a key driver in forming
PMAC, and continuing our outreach strategy."
About Pure Global Cannabis
Pure Global Cannabis Inc. is an innovation-based cannabis
company led by experienced pharma, biotechnology, horticultural,
and consumer packaged goods (CPG) experts. The Company's wholly
owned subsidiary, PureSinse Inc., is a licensed producer under the
Cannabis Act. The Company's Brampton campus houses facilities for
vertically farmed cultivation, R&D, extraction, manufacturing,
and distribution. Pure Global will produce branded and
white-labeled cannabis products for the medical, pharmaceutical,
wellness, health & beauty, natural health, food & beverage,
craft, and recreational legal markets with uniquely formulated and
purified concentrates and dried flower. The Company is using the
Canadian market as a springboard to develop and manufacture
GMP-compliant premium quality cannabis products for international
sale and distribution with a goal to become one of the most trusted
premium international cannabis brands.
FORWARD-LOOKING STATEMENTS
This news release contains certain forward-looking statements,
including, but not limited to, statements about Pure Global's
future plans and intentions. Wherever possible, words such as
"may", "will", "should", "could", "expect", "plan", "intend",
"anticipate", "believe", "estimate", "predict" or "potential" or
the negative or other variations of these words, or similar words
or phrases, have been used to identify these forward-looking
statements. These statements reflect management's current beliefs
and are based on information currently available to management as
at the date hereof.
Forward-looking statements involve significant risk,
uncertainties and assumptions. Many factors could cause actual
results, performance or achievements to differ materially from the
results discussed or implied in the forward-looking statements.
These factors should be considered carefully, and readers should
not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this news
release are based upon what management believes to be reasonable
assumptions, Pure Global cannot assure readers that actual results
will be consistent with these forward-looking statements. These
forward-looking statements are made as of the date of this news
release, and Pure Global assumes no obligation to update or revise
them to reflect new events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this
release.
To register to Pure Global's mailing list, please visit
www.pureglobal.com. Follow @pureglobalcanna on Twitter and
Facebook and @pureglobalcannabis on Instagram.
SOURCE Pure Global Cannabis Inc.